APA (7th ed.) Citation

Branford, S., & Müller, M. C. (2012). Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. Journal of clinical oncology. [Englische Ausgabe], 30(35), .

Chicago Style (17th ed.) Citation

Branford, Susan, and Martin Christian Müller. "Initial Molecular Response at 3 Months May Predict Both Response and Event-free Survival at 24 Months in Imatinib-resistant or -intolerant Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Treated with Nilotinib." Journal of Clinical Oncology. [Englische Ausgabe] 30, no. 35 (2012).

MLA (9th ed.) Citation

Branford, Susan, and Martin Christian Müller. "Initial Molecular Response at 3 Months May Predict Both Response and Event-free Survival at 24 Months in Imatinib-resistant or -intolerant Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Treated with Nilotinib." Journal of Clinical Oncology. [Englische Ausgabe], vol. 30, no. 35, 2012.